WallStSmart
COR

Cencora Inc.

NYSE: COR · HEALTHCARE · MEDICAL DISTRIBUTION

$311.43
-0.18% today

Updated 2026-04-29

Market cap
$59.95B
P/E ratio
37.04
P/S ratio
0.18x
EPS (TTM)
$8.32
Dividend yield
0.72%
52W range
$269 – $377
Volume
1.3M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Cencora Inc. (COR) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$311.43
Consensus
$395.23
+26.91%
2030 Target
—
—
DCF
$1,254.62
+70.85% MoS
13 analysts:
7 Buy2 Hold0 Sell

Management guidance

Cencora reaffirmed FY2026 adjusted diluted EPS guidance of $17.45-$17.75 as of April 2026. The company lifted its FY2026 sales outlook during Q1 earnings (Feb 2026), indicating confidence in mid-to-high single-digit revenue growth. CEO Robert P. Mauch has emphasized specialty care expansion and international growth as key drivers, but no specific multi-year revenue targets (e.g., '$X billion by 2030') have been publicly disclosed.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$43,815.52
—
Base case (2030)
$26,276.32
—
Bear case (2030)
$17,539.20
—

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)
Revenue$262.2B$294.0B$321.3B$350.0B$373.9B$399.2B$426.1B
Revenue growth—12.1%9.3%8.9%6.8%6.8%6.7%
EPS$11.99$13.76$2.87$17.80$19.89$22.10$24.50
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$21,599.20$23,060.80$24,619.84$26,276.32

Catalysts & risks

Growth catalysts
+ EyeSouth Partners retina division acquisition ($1.1B) closing by Sept 2026 — expands high-margin specialty ophthalmology services
+ MWI Animal Health merger with Covetrus ($3.5B) — strengthens specialty distribution platform and creates revenue synergies
+ CFO transition (James Cleary retiring June 30, 2026) — may signal new capital allocation strategy or M&A acceleration under successor
+ Specialty care and international segment acceleration — CEO has highlighted these as high-growth areas within the distribution business
+ Gross margin expansion from specialty mix shift — higher-margin specialty pharmaceuticals growing faster than commodity generics
Key risks
- US prescription drug pricing reform headwinds — generic pricing erosion and regulatory pricing pressure similar to industry peers (McKesson, Cardinal Health)
- International operations underperformance — recent news indicates international challenges offsetting US specialty growth
- Market saturation in core pharmaceutical distribution — mature US generic drug market limits volume growth to low single digits
- Integration execution risk — $1.1B EyeSouth and $3.5B Covetrus mergers must deliver projected synergies; CFO transition adds execution uncertainty
- Competitive intensity from McKesson and Cardinal Health — both pursuing identical specialty distribution strategies, limiting Cencora's pricing power and market share gains

Methodology

Cencora Inc.'s forward estimates are derived from AI-powered research synthesis combining analyst consensus from 13 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.